Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

Cancer research - 15 Jan 2008

Gilmer Tona M, Cable Louann, Alligood Krystal, Rusnak David, Spehar Glenn, Gallagher Kathleen T, Woldu Ermias, Carter H Luke, Truesdale Anne T, Shewchuk Lisa, Wood Edgar R

Abstract excerpt

The goal of this study was to characterize the effects of non-small cell lung carcinoma (NSCLC)-associated mutations in epidermal growth factor receptor (EGFR/ErbB1) and HER2 (ErbB2) on interactions with the dual tyrosine kinase inhibitor lapatinib. Biochemical studies show that commonly observed variants of EGFR [G719C, G719S, L858R, L861Q, and Delta746-750 (del15)] are enzyme activating, increasing the tyrosine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CHO Cells
Share to Cricetulus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Genes, erbB-2

Share to Lapatinib

Share to Mutant Proteins

Share to Quinazolines

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 18199554
DOI: 10.1158/0008-5472.CAN-07-2404

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.PMID 18199554Read ↗

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.Semantic proximity Read ↗

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.Semantic proximity Read ↗

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.Semantic proximity Read ↗

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.Semantic proximity Read ↗

A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer.Semantic proximity Read ↗

The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2Semantic proximity Read ↗

Structure and clinical relevance of the epidermal growth factor receptor in human cancer.Semantic proximity Read ↗

Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.Semantic proximity Read ↗

Activating HER2 mutations in HER2 gene amplification negative breast cancer.Semantic proximity Read ↗

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.Semantic proximity Read ↗

Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.Semantic proximity Read ↗

A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.